Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates
August 12, 2021 08:00 ET
|
Century Therapeutics, Inc.
Continued Company investment across our iPSC platforms, programs, and manufacturingLead program, CNTY-101, remains on track for IND filing in mid-2022Recent IPO with net proceeds of approximately...
Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 22, 2021 16:01 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, June 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics Announces Pricing of Initial Public Offering
June 17, 2021 18:15 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, June 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology,...